Genentech, a member of the Roche Group (RHHBY), announced that its Phase III INShore study evaluating Gazyva (obinutuzumab) in children and young adults aged 2 to 25 years with idiopathic nephrotic syndrome (INS) achieved statistically significant and clinically meaningful results.
The study met its primary endpoint, with more participants achieving sustained complete remission at one year (week 52) with Gazyva compared to mycophenolate mofetil (MMF). Sustained complete remission was defined as the absence of relapses and a urine protein-to-creatinine ratio of 0.2 or less at week 52. Several key secondary endpoints were also met.
No new safety signals were identified, and the safety profile remained consistent with Gazyva's established use in adults.
In addition to idiopathic nephrotic syndrome, Gazyva is being investigated in membranous nephropathy, lupus nephritis, rare immune-mediated kidney diseases and systemic lupus erythematosus.
Gazyva is also approved in 100 countries for various types of hematological cancers. In the U.S., Gazyva is part of a collaboration between Genentech and Biogen.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.